LONDON (Reuters) Jun 14 – A British biotech firm said on Friday that early tests of an anti-smoking vaccine showed it was safe and that it effectively produced antibodies against nicotine.
Xenova Plc said the first ever clinical trial of the anti-smoking vaccine showed that its product, TA-NIC, generated antibodies that bind to nicotine. The firm, which is also developing a vaccine against cocaine, believes that if it can stop nicotine from reaching the brain, it can solve smokers’ addiction
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!